ocrelizumab
Pronunciation: oh-krel-IZ-u-mab
A humanized anti-CD20 monoclonal antibody approved for both relapsing and primary progressive multiple sclerosis.
Full Definition
Ocrelizumab is a humanized monoclonal antibody that selectively targets CD20-positive B lymphocytes, causing B-cell depletion through complement-dependent cytotoxicity and antibody-dependent cellular phagocytosis. It represents a significant advancement in multiple sclerosis treatment as the first therapy approved for primary progressive MS and has demonstrated superior efficacy compared to interferon in relapsing forms. The drug is administered as intravenous infusions every six months and requires monitoring for infusion reactions and increased infection risk. Ocrelizumab's approval was based on its ability to reduce both relapse rates and disability progression, highlighting the important role of B cells in MS pathogenesis.
Usage
Usage note: Brand name Ocrevus should be capitalized; first approved therapy for primary progressive MS.
In Context
- "Ocrelizumab significantly reduced disability progression in primary progressive multiple sclerosis patients." — Clinical trial results
- "The patient experienced mild infusion reactions during ocrelizumab administration." — Treatment monitoring note